MR 16. Effectiveness of testosterone undecanoate treatment in men with asthenospermia

Objective: To assess the effectiveness of testosterone undecanoate on sperm motility and pregnancy incidence in men with asthenospermia.

Design: Retrospective and clinical trial.

Participants: Fifty men with asthenospermia.

Interventions: Patients were randomized to rec

Main outcome measures: Pregnancy incidence and sperm characteristics after 1, 2 and 3 months of medication and 3 months after the end of the trial.

Results: Compared with the placebo, T undecanoate treatment produced a satisfactory improvement of seminal motility (F=55.904, P=0.000). In the groups treated with T undecanoate, the incidence of pregnancy was 28.2% while the incidence of pregnancy of placebo groups was 11.1%. In active treatment groups, twenty six people took T undecanoate for more than 3 months. In the 3 months, semen volume showed no statistical difference (F=1.206, P=0.312) before and after treatment, sperm concentration and motility showed statistical difference. Motility grade a showed significantly higher increment in 2 and 3 months after treatment than 1 month and there was no statistical difference between 2 and 3 months. So did grade b.

Conclusions: The results indicate that T undecanoate decreases sperm concentration and increases seminal motility, leading to a higher incidence of pregnancy in couples with infertility related to asthenoaspermia.